TipRanks
Advertisement
Advertisement

MX:AGIO Stock Latest News

Agios Pharmaceuticals price target raised to $50 from $46 at BofA
The FlyAgios Pharmaceuticals price target raised to $50 from $46 at BofA
11h ago
AGIO
Agios Pharmaceuticals Signals Momentum Amid Ongoing Losses
PremiumCompany Announcements
Agios Pharmaceuticals Signals Momentum Amid Ongoing Losses
1M ago
AGIO
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
PremiumThe Fly
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
2M ago
AGIO
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
PremiumRatings
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
2M ago
AGIO
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
PremiumRatings
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
2M ago
AGIO
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
PremiumThe FlyAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
2M ago
AGIO
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
Premium
The Fly
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
2M ago
AGIO
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
AGIO
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
PremiumRatingsAgios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
2M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >